EOS Imaging has raised US$51 million in its IPO on NYSE Euronext

Venture-backed medical device company EOS Imaging has raised US$51 million in its IPO on NYSE Euronext. Based on the opening trade price, the company is valued at approximately US$146 million. Investors include medical device-focused venture capital firm NBGI Ventures and Edmond de Rothschild Investment Partners, which has been the lead investor and the company’s largest shareholder since 2005.

EOS Imaging designs, develops and markets EOS, a medical imaging system revolutionizing the treatment chain of the main osteoarticular diseases (hips, knees, back) and related orthopedic surgery. Based on the work of Physics Nobel Prize Winner Georges Charpak, the EOS system is the first imaging solution capable of producing, in one step, a 2D and 3D image of the upright skeleton with a very low radiation dose. EOS 2D/3D images are produced in the patient’s natural functional position, raising the accuracy of diagnosis, surgery and osteoarticular pathological follow-up.

The success of the IPO confirms EOS Imaging’s outstanding technology pedigree, its sound commercial and clinical proposition and its potential for strong commercial growth on a global level.

Oaklins’ team in France was appointed by the shareholders of EOS Imaging to launch an initial public offering and proposed listing of the company’s shares on compartment C of the regulated market of NYSE Euronext.